Meticulous Research®, a renowned global market research firm, has released a comprehensive report titled ‘Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography [X-ray, CT], Molecular [NAAT, WGS, Rapid], Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage – Global Forecast to 2031’. According to the latest publication, the tuberculosis diagnostics market is expected to reach $3.56 billion by 2031, growing at a CAGR of 5.0% from 2024 to 2031.
Request For Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=5885?
Market Growth Drivers
The market’s expansion is primarily attributed to the rising prevalence of tuberculosis in low- and middle-income countries, the emergence of drug-resistant TB strains, and favorable government initiatives promoting tuberculosis diagnosis and treatment. Additionally, various awareness programs organized by governments and global organizations to educate the public about tuberculosis are anticipated to offer significant growth opportunities for companies operating within the market.
Key Players in the Market
Several major companies are leading the tuberculosis diagnostics market, including F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), and Creative Diagnostics (U.S.).
Future Outlook for the Tuberculosis Diagnostics Market
The tuberculosis diagnostics market is segmented by test type, infection stage, end user, and geography. Additionally, the report evaluates major industry competitors and provides analysis at both regional and country levels.
Test Type Segmentation
In terms of test types, the market is categorized into skin test/Mantoux, radiographic tests, molecular tests, sputum smear microscopy, culture & drug resistance tests, and other test types. The skin test/Mantoux segment is expected to dominate the market in 2024, accounting for 38.2% of the total share. The significant share of this segment is due to its simplicity, affordability, and widespread availability, even in small clinics and remote areas. Additionally, the high utilization of skin tests for diagnosing latent tuberculosis has further strengthened the segment’s position in the market. For instance, research indicates that the cost of a TB skin test is around USD 37, while Interferon Gamma Release Assay (IGRA) costs approximately USD 89.
Infection Stage Segmentation
The tuberculosis diagnostics market is divided into two categories based on infection stage: active tuberculosis and latent tuberculosis. The active TB segment is projected to experience the highest CAGR from 2024 to 2031. The primary factors driving this growth are the increasing prevalence of tuberculosis in lower-income regions, initiatives by governments and public health organizations to manage the TB burden, and a rise in TB outbreaks worldwide.
End User Segmentation
In terms of end users, the market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The diagnostic laboratories segment is anticipated to register the highest growth during the forecast period. This is mainly due to the advanced technologies available in laboratories, such as next-generation sequencing, which allows for more accurate diagnoses. Additionally, government initiatives and efforts to raise awareness about tuberculosis are further expected to contribute to the growth of this segment.
Regional Insights and Opportunities in Asia-Pacific
Asia-Pacific as a Growth Hub
The tuberculosis diagnostics market is analyzed across major regions, including North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (Japan, China, India, Indonesia, Thailand, Singapore, Philippines, Australia, Rest of Asia-Pacific), Latin America, Middle East, and Africa (South Africa, Nigeria, Kenya, Rest of Africa). Among these regions, Asia-Pacific is projected to record the highest CAGR during the forecast period.
India and China Leading the Market
Within Asia-Pacific, countries like India and China present lucrative growth opportunities for market players. The large populations and high TB burden in these nations are the primary factors driving demand for diagnostic tools and technologies. Moreover, both countries are experiencing economic growth, which has led to increased healthcare investments and the development of healthcare infrastructure, further supporting the expansion of the tuberculosis diagnostics market.
Buy Now: https://www.meticulousresearch.com/Checkout/14457940?
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to detail. With meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research